213250-64-7

Usage

Uses

Used in Pharmaceutical Industry:
[2-[(3'R,5'R)-3',5'-bis[(tert-butyldimethylsilyl)oxy]-4'-methylenecyclohexylidene]ethyl]diphenylphosphine oxide is used as an intermediate in the synthesis of vitamin D3 analogs. These analogs are essential for various biological functions, including regulation of calcium and phosphorus metabolism, bone health, and immune system modulation. The compound plays a crucial role in the development of pharmaceuticals targeting these applications.
Used in Chemical Synthesis:
In the chemical synthesis industry, [2-[(3'R,5'R)-3',5'-bis[(tert-butyldimethylsilyl)oxy]-4'-methylenecyclohexylidene]ethyl]diphenylphosphine oxide can be utilized as a building block or reagent for the creation of more complex molecules. Its unique structure and functional groups make it a valuable component in the synthesis of various organic compounds, potentially leading to new materials and applications in different fields.

Upstream product

• 829-85-6 diphenylphosphane 
• 213250-63-6 2-((3R,5R)-3,5-bis(tertbutyldimethylsilyloxy)-4-methylenecyclohexylidene)ethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 77-95-2 D-(-)-quinic acid 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 163217-18-3 (1R,3R,4S,5R)-3-[(tert-butyldimethylsilyl)oxy]-1,4-dihydroxy-6-oxa-bicyclo[3.2.1]octan-7-one 
• 766529-94-6 (1R,3R,5R)-3-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-6-oxa-bicyclo[3.2.1]octane-4,7-dione 
• 766529-88-8 (1R,3R,5R)-1-acetoxy-3-[(tert-butyldimethylsilyl)oxy]-6-oxa-bicyclo[3.2.1]octane-4,7-dione 
• 213250-59-0 methyl (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-methylenecyclohexanecarboxylate 
• 213250-60-3 [(3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-methylenecyclohexyl]methanol 
• 213250-58-9 (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-oxocyclohexanecarboxylic acid methyl ester 
• 213250-62-5 methyl-2-((3R,5R)-3,5-bis(tertbutyldimethylsilyloxy)-4-methylenecyclohexylidene)acetate 
• 213250-61-4 (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-4-methylenecyclohexanone 
• 135711-62-5 methyl quinicate 

Downstream Products

• 364059-43-8 (1R,3aS,7aR)-4-[2-[(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-4-methylene-cyclohexylidene]-eth-(E)-ylidene]-1-((S)-5-ethyl-1-methyl-5-triethylsilanyloxy-heptyl)-7a-methyl-octahydro-indene 
• 364059-48-3 (1R,3aS,7aR)-4-[2-[(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-4-methylene-cyclohexylidene]-eth-(E)-ylidene]-7a-methyl-1-[(S)-1-methyl-4-(1-triethylsilanyloxy-cyclopentyl)-butyl]-octahydro-indene 
• 213319-29-0 2-methylidene-19-nor-1α,25-dihydroxyvitamin D3 
• 213250-70-5 (20S)-2-methylene-19-nor-1α,25-dihydroxyvitamin D₃ 
• 213250-69-2 (1R,3aS,7aR)-4-[2-[(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-4-methylene-cyclohexylidene]-eth-(E)-ylidene]-1-((S)-1,5-dimethyl-5-triethylsilanyloxy-hexyl)-7a-methyl-octahydro-indene 
• 852658-66-3 C₃₅H₆₄O₂Si₂ 
• 852658-61-8 C₃₄H₆₂O₂Si₂ 
• 852658-76-5 C₃₆H₆₆O₂Si₂ 
• 213250-65-8 (1R,3R,7E,17β)-1,3-bis{[tert-butyl(dimethyl)silyl]oxy}-2-methylidene-17-{6-methyl-6-[(triethylsilyl)oxy]heptan-2-yl}-9,10-secoestra-5,7-diene 

Relevant academic research and scientific papers

Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects

We have synthesized a novel vitamin D receptor agonist VS-105 ((1R,3R)-5-((E)-2-((3αS,7αS)-1-((R)-1-((S)-3-hydroxy-2, 3-dimethylbutoxy)ethyl)-7α-methyldihydro-1H-inden-4(2H,5H,6H,7H,7αH) -ylidene)ethylidene)-2-methylenecyclohexane-1,3-diol). Preparation o

VITAMIN D RECEPTOR AGONISTS AND USES THEREOF

Disclosed is a compound of Formula (I), in which R1, R2, R3, R4, R5, R6, X, and a are defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition comprising a compound or salt therof of Formula (I) and a method of treating a disease which benefits from the modulation of the vitamin D receptor, such as a bone disorder, cardiovascular disease, a cardiovascular complication associated with renal disease, endothelial dysfunction, hyperparathyroidism, hypocalcemia, an immune disorder, left ventricular hypertrophy, a proliferative disease, proteinuria, renal disease, and thrombosis.

2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES FOR THE TREATMENT OF OSTEOGENESIS IMPERFECTA

The present invention relates to the treatment of ostogenesis imperfecta by adminstering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative, optionally with a bisphosphonate. Particularly, the present invention relates to the treatmen

Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and aromatase inhibitors

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an aromatase inhibitor. Particularly, the present i

Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a growth hormone secretagogue

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and a growth hormone secretagogue or a pharmaceutically

2-alkylidene-19-nor-vitamin D derivatives for the treatment or prevention of a secon hip fracture

The present invention relates to methods of treating or preventing a second hip fracture, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods

2-alkylidene-19-nor-vitamin D derivatives for the treatment of osteopenia or male osteoporosis

The present invention relates to methods of treating osteopenia or male osteoporosis, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods of t

2-Alkylidene-19-nor-vitamin D derivatives for the treatment of osteosarcoma

The present invention relates to methods of treating osteosarcoma, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods of treating osteosarcom

2-alkylidene-19-nor-vitamin D derivatives for the treatment of hypogonadism or andropause

The present invention relates to methods of treating hypogonadism or andropause, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods of treati

2-Alkylidene-19-nor-vitamin D derivatives for the treatment of frailty, muscle damage or sarcopenia

The present invention relates to methods of treating frailty, muscle damage or sarcopenia, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods